Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)

NCT07222956 is registered in ClinicalTrials.gov with Moein Amin as lead sponsor.

NCT NCT07222956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07222956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)
Lead sponsor
Moein Amin
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2027
Completion date
December 30, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis (ms) - relapsing-remitting, multiple sclerosis (ms) primary progressive, multiple sclerosis (ms) secondary progressive